No Data
No Data
This 'Venture Creator' Helped Launch Moderna. Now He's Harnessing AI to Find New Drugs. -- Barron's
What Makes Tempus AI (TEM) an Attractive Investment?
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting With HER2
TD Cowen Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $50
Maintained Buy Rating for Tempus AI, Inc. Class A Amid Inconsequential Financial Adjustments
Tempus AI, Remix Therapeutics Expand Data, Sequencing Collaboration
DJMA : you saying it will go up? could not see clearly
Sean Parker OP DJMA : looks like either a double bottom or inverted head and shoulders to me. I could be wrong but the pt is 49.